Compare SIF & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIF | ENTX |
|---|---|---|
| Founded | 1913 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 147.4M |
| IPO Year | 1995 | 2015 |
| Metric | SIF | ENTX |
|---|---|---|
| Price | $20.28 | $2.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 37.0K | ★ 671.8K |
| Earning Date | 08-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.67 | N/A |
| EPS | ★ 0.71 | 0.22 |
| Revenue | ★ $111,212,000.00 | $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.99 | ★ $13.68 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.88 | $0.91 |
| 52 Week High | $29.00 | $4.20 |
| Indicator | SIF | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.36 | 53.62 |
| Support Level | $20.27 | $2.71 |
| Resistance Level | $20.39 | $3.08 |
| Average True Range (ATR) | 1.12 | 0.20 |
| MACD | -0.26 | 0.05 |
| Stochastic Oscillator | 7.55 | 55.76 |
SIFCO Industries Inc produces forgings, sub-assemblies, and machined components for the Aerospace and Energy markets. Its services include forging, heat treating, machining, surface treatment, non-destructive testing, and sub-assembly of forged components. The company manufactures envelopes and precision forgings, as well as rough and finished machined parts, serving OEMs, Tier 1 and Tier 2 suppliers, and aftermarket providers across Aerospace, Defense, Energy, and Commercial Space. Its Products are made from steel, high-temperature alloys, nickel alloys, titanium, and aluminum, and include components for aircraft and industrial gas turbine engines, airframe structures, landing gear, wheels and brakes, helicopter rotating parts, and other commercial and industrial applications.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.